|
|
| HUMAN GENOME SCIENCES TO HOST CONFERENCE CALL TO DISCUSS THIRD QUARTER 2003 FINANCIAL RESULTS | |
|
ROCKVILLE, Maryland – October 23, 2003 – Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that it plans to announce its financial results for the three months and nine-months period ended September 30, 2003, in a press release before the opening of the U.S. financial markets on Tuesday, October 28, 2003. Human Genome Sciences will hold a conference call on that same day to discuss these results. The conference call will be hosted by senior management and will be held on Tuesday, October 28, 2003, at 10:00 am Eastern Time. Investors may listen to the call by dialing 719/867-0640 or 800/314-7867, meeting number 167192, five to ten minutes before the start of the call. A reply of the conference call will be available several hours after the conference call by dialing 719/457-0820 or 888/203-1112 and will remain available for several days. This conference call also will be webcast and may be accessed at www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days. Human Genome Sciences is a company with the mission to treat and cure disease by bringing new gene-based drugs to patients. HGS and Human Genome Sciences are registered trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company’s web site at www.hgsi.com. For additional information on Human Genome Sciences, Inc., visit the company’s web site at www.hgsi.com This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences’ current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company’s unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company’s ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company’s depended on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company’s filing with the Securities and Exchange Commission. Existing and prospective Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
CONTACT: |